Visit Booth #751 and access ePoster 51372 at the Poster Exhibit Presentation Center
See ePoster 51372: “Barzolvolimab demonstrates safety and clinically meaningful activity as early as two weeks in moderate to severe prurigo nodularis.” Barzolvolimab is an investigational drug that has not been reviewed and approved for safety and efficacy by the FDA.